MannKind Corp. Coverage Initiated by Analysts at Brinson Patrick (MNKD)

Brinson Patrick initiated coverage on shares of MannKind Corp. (NASDAQ: MNKD) in a research note issued on Friday, Analyst Ratings Network reports. The firm set an “outperform” rating on the stock.

Several other analysts have also recently commented on the stock. Analysts at Merrill Lynch downgraded shares of MannKind Corp. from a “buy” rating to a “neutral” rating in a research note to investors on Friday, June 7th. Separately, analysts at Bank of America downgraded shares of MannKind Corp. from a “buy” rating to a “neutral” rating in a research note to investors on Friday, June 7th. They now have a $8.00 price target on the stock, up previously from $5.00. Finally, analysts at MLV Capital initiated coverage on shares of MannKind Corp. in a research note to investors on Wednesday, May 15th. They set a “buy” rating and a $6.00 price target on the stock.

Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $6.25.

MannKind Corp. (NASDAQ: MNKD) traded down 2.38% on Friday, hitting $6.56. MannKind Corp. has a 1-year low of $1.57 and a 1-year high of $4.50. The stock’s 50-day moving average is currently $3.. The company’s market cap is $1.839 billion.

MannKind Corp. (NASDAQ: MNKD) last announced its earnings results on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.15). On average, analysts predict that MannKind Corp. will post $-0.48 earnings per share for the current fiscal year.

MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.

http://www.watchlistnews.com/2013/06/24/mannkind-corp-coverage-initiated-by-analysts-at-brinson-patrick-mnkd/